← Companies|Viking Therapeutics
VK

Viking Therapeutics

VKTX·NASDAQSan Diego CAFounded 201245 employees
Mid CapbiotechPublicMetabolic
Platform: Dual GLP-1/GIP
Market Cap
$6B
All Drugs
4
Clinical Trials
8
Failed / Terminated
3
FDA Approved
1
Stock Price & Catalysts (VKTX)
Loading VKTX stock data...
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
VKT-4052VKT-4052Phase 2/32Small MoleculeTNFαWRNiEpilepsy
VKT-6548VKT-6548Phase 2/31Gene EditingPD-L1Cl18.2Prostate Ca
TirasotorasibVKT-5480Phase 11Fusion ProteinCFTRIL-23iMMWet AMD
VoxaderotideVKT-2923Approved4Bispecific AbPD-L1HER2PsA
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (8)
2025-05-03
VKT-4052 Ph3 Readout
Epilepsy
Past
2025-12-09
VKT-4052 Orphan Drug
Epilepsy
Past
2026-08-21
Voxaderotide Ph3 Readout
PsA
Ph3 Readout
2029-06-15
Voxaderotide Ph3 Readout
PsA
Ph3 Readout
2031-04-18
VKT-4052 Ph3 Readout
Epilepsy
Ph3 Readout
2031-05-27
VKT-6548 Ph3 Readout
Prostate Ca
Ph3 Readout
2031-08-16
Voxaderotide Ph3 Readout
PsA
Ph3 Readout
2031-09-10
Voxaderotide Ph3 Readout
PsA
Ph3 Readout